Home/Pipeline/HIV mAb Program

HIV mAb Program

HIV

Pre-clinicalActive

Key Facts

Indication

HIV

Phase

Pre-clinical

Status

Active

Company

Adnexus

About Adnexus

Adnexus is a private, pre-revenue biotech company pioneering an AI-driven approach to monoclonal antibody discovery against infectious diseases. Its core technology, the Sutra™ platform, analyzes viral targets to identify immutable epitopes and facilitates rapid antibody generation from human B-cells of recovered patients. The company has demonstrated proof-of-concept by identifying conserved targets for HIV, SARS-CoV-2, and Monkeypox, positioning itself in the high-need market for broad-spectrum antiviral therapeutics.

View full company profile

Therapeutic Areas

Infectious Diseases

Other HIV Drugs

Drug	Company	Phase	Status
Vaxine HIV Vaccine	Vaxine	Preclinical	Active
OraQuick® HIV Self-Test	OraSure	Commercial	FDA Approved; Marketed
Tenofovir Disoproxil Fumarate	Hetero	Commercial	Active
NanoDDI	Continuity Biosciences	Pre-clinical	Active
HIV Gene Therapy	Nanite	Pre-clinical	Active
RGFields for HIV	Anapole Technologies	Clinical (phase unspecified)	Active
Undisclosed Program	EnnoDC	Phase 1	Active
O2-16 Series	OyaGen	Preclinical	Active
SBX 2048	Stramsen Biotech	Early-stage Clinical	Active
ALF Platform	Senzo	Pre-clinical	Active
Gilead HIV Franchise	Royalty Pharma	Marketed	Active
ANKTIVA-based regimens	ImmunityBio	Phase 1/2	Active